IPAD-DB ID | C00651 |
Name | Ginsenoside Rb1 |
Category | Natural compounds |
2D Structure |
|
3D Structure | |
Molecular Formula | C 5 4 H 9 2 O 2 3 |
Molecular Weight | 1109.3 g/mol |
IUPAC Name | (2R, 3R, 4S, 5S, 6R)-2-[[(2R, 3S, 4S, 5R, 6S)-6-[(2S)-2-[(3S, 5R, 8R, 9R, 10R, 12R, 13R, 14R, 17S)-3-[(2R, 3R, 4S, 5S, 6R)-4, 5-dihydroxy-6-(hydroxymethyl)-3-[(2S, 3R, 4S, 5S, 6R)-3, 4, 5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-12-hydroxy-4, 4, 8, 10, 14-pentamethyl-2, 3, 5, 6, 7, 9, 11, 12, 13, 15, 16, 17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-2-yl]oxy-3, 4, 5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3, 4, 5-triol |
InChI | InChI=1S/C54H92O23/c1-23(2)10-9-14-54(8, 77-48-44(69)40(65)37(62)29(74-48)22-70-46-42(67)38(63)34(59)26(19-55)71-46)24-11-16-53(7)33(24)25(58)18-31-51(5)15-13-32(50(3, 4)30(51)12-17-52(31, 53)6)75-49-45(41(66)36(61)28(21-57)73-49)76-47-43(68)39(64)35(60)27(20-56)72-47/h10, 24-49, 55-69H, 9, 11-22H2, 1-8H3/t24-, 25+, 26+, 27+, 28+, 29+, 30-, 31+, 32-, 33-, 34+, 35+, 36+, 37+, 38-, 39-, 40-, 41-, 42+, 43+, 44+, 45+, 46+, 47-, 48-, 49-, 51-, 52+, 53+, 54-/m0/s1 |
InChIKey | GZYPWOGIYAIIPV-JBDTYSNRSA-N |
Canonical SMILES | CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)OC7C(C(C(C(O7)COC8C(C(C(C(O8)CO)O)O)O)O)O)O)C |
PubChem CID | 9898279 |
DrugBank Accession Number | DB06749 |
CAS Registry Number | 41753-43-9 |
Molecular Weight(Computed by SwissADME) | 1109.29 |
Hac(Computed by SwissADME) | 77 |
Volume(Computed by ADMETlab 2.0) | 1073.627 |
Density(Computed by ADMETlab 2.0) | 1.033 |
nRing(Computed by ADMETlab 2.0) | 8 |
MaxRing(Computed by ADMETlab 2.0) | 17 |
nHet(Computed by ADMETlab 2.0) | 23 |
fChar(Computed by ADMETlab 2.0) | 0 |
nRig(Computed by ADMETlab 2.0) | 45 |
Flexibility(Computed by ADMETlab 2.0) | 0.356 |
Stero Centers(Computed by ADMETlab 2.0) | 30 |
LogS(Computed by ADMETlab 2.0) | -1.62 |
LogD(Computed by ADMETlab 2.0) | 1.161 |
logP(Computed by ADMETlab 2.0) | -0.392 |
TPSA(Computed by SwissADME) | 377.29 |
Hbond Acceptor(Computed by SwissADME) | 23 |
Hbond Donor(Computed by SwissADME) | 15 |
Rotatable Bonds(Computed by SwissADME) |
GI Absorption(Computed by SwissADME) | Low |
BBB(blood-brain barrier) Permeant(Computed by SwissADME) | No |
P-gp Substrate(Computed by SwissADME) | Yes |
CYP1A2 Inhibitor(Computed by SwissADME) | No |
CYP2C19 Inhibitor(Computed by SwissADME) | No |
CYP2C9 Inhibitor(Computed by SwissADME) | No |
CYP2D6 Inhibitor(Computed by SwissADME) | No |
CYP3A4 Inhibitor(Computed by SwissADME) | No |
log Kp(Skin Permeation)(Computed by SwissADME) | -12.87 |
Lipinski(Computed by SwissADME) | 3 |
Ghose(Computed by SwissADME) | 4 |
Veber(Computed by SwissADME) | 2 |
Egan(Computed by SwissADME) | 1 |
Muegge(Computed by SwissADME) | 6 |
Bioavailability Score(Computed by SwissADME) | 0.17 |